Form 4: Edgewise Therapeutics CFO R. Michael Carruthers Reports Stock Option and RSU Grant
SEC Form 4 Filing
R. Michael Carruthers, CFO of Edgewise Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on August 12, 2024.
Summary
- R. Michael Carruthers, the Chief Financial Officer of Edgewise Therapeutics, Inc. (EWTX), filed a Form 4 on August 14, 2024.
- The filing reports the grant of stock options and restricted stock units (RSUs) on August 12, 2024.
- Carruthers acquired options to purchase 138,750 shares of common stock at an exercise price of $17.05.
- These options vest monthly over four years, starting August 12, 2024.
- He also received 23,125 RSUs, each representing a contingent right to receive one share of Edgewise Therapeutics common stock.
- These RSUs vest in four equal annual installments beginning on August 12, 2024.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral-positive signal.
Positives
- The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
- The vesting schedules incentivize long-term commitment and performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service by the CFO.
Industry Context
Stock option and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options and RSUs to their executives.
- The vesting schedules (monthly for options, annual for RSUs) are typical for these types of grants, designed to retain key personnel and incentivize long-term value creation.
Stakeholder Impact
- The grant of stock options and RSUs can positively impact shareholders by aligning management's interests with long-term company performance.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the stock option and RSU grant. |
| 08/12/2024 | Start date for monthly vesting of stock options. |
| 08/12/2024 | Start date for annual vesting of RSUs. |
| 08/12/2034 | Expiration date of the stock options. |
| 08/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.